Published in Cancer Res on December 15, 2000
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet (2004) 1.21
Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol (2003) 1.00
Case-control study and meta-analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk. Br J Cancer (2008) 0.95
Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: a case-series study. Breast Cancer Res (2005) 0.94
Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients' survival. World J Gastroenterol (2005) 0.88
Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors. J Cancer Res Clin Oncol (2007) 0.87
Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue. J Exp Clin Cancer Res (2010) 0.84
Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol (2003) 0.83
Genetic polymorphisms and linkage disequilibrium of sulfotransferase SULT1A1 and SULT1A2 in a Korean population: comparison of other ethnic groups. Eur J Clin Pharmacol (2005) 0.82
SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study. Breast Cancer Res (2005) 0.81
Molecular cloning and functional analysis of porcine SULT1A1 gene and its variant: a single mutation SULT1A1 causes a significant decrease in sulfation activity. Mamm Genome (2004) 0.81
A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer. J Cancer Res Clin Oncol (2006) 0.79
Sulfotransferase 1A1 Arg(213)His polymorphism and prostate cancer risk. Exp Ther Med (2011) 0.78
Pharmacogenetics of SULT1A1. Pharmacogenomics (2014) 0.75
Sulfotransferase SULT1A1 Arg213His polymorphism with cancer risk: a meta-analysis of 53 case-control studies. PLoS One (2014) 0.75
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41
Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell (1990) 8.30
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Analysis of human transcriptomes. Nat Genet (1999) 6.14
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 5.12
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell (2001) 5.05
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev (1995) 4.94
Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell (1999) 4.87
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med (1997) 3.84
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell (1994) 3.74
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet (1997) 3.66
Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature (2001) 3.50
Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc Natl Acad Sci U S A (1991) 3.43
Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet (1994) 3.32
Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science (1993) 3.28
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med (1996) 3.04
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell (1999) 2.92
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Germ-line msh6 mutations in colorectal cancer families. Cancer Res (1999) 2.68
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet (1994) 2.66
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA (2000) 2.58
Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene (1998) 2.56
Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet (1998) 2.56
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA (1993) 2.51
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA (1995) 2.50
LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res (2001) 2.48
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax (1997) 2.46
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1998) 2.46
British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Exp Allergy (2010) 2.44
BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy (2015) 2.37
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res (2001) 2.22
Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev (1991) 2.20
Statistical methods for polyploid radiation hybrid mapping. Genome Res (1995) 2.15
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA (1999) 2.14
Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst (1998) 2.13
Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene (1992) 2.13
Identification of a new virulence locus in Agrobacterium tumefaciens that affects polysaccharide composition and plant cell attachment. J Bacteriol (1987) 2.08
Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain). Virology (1983) 2.06
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst (2001) 2.02
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J (1995) 2.02
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med (1997) 1.97
Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.96
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res (1995) 1.95
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev (2001) 1.95
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res (1994) 1.95
Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res (1992) 1.93
Artificial neural networks improve the accuracy of cancer survival prediction. Cancer (1997) 1.91
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.89
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A (1992) 1.87
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Multidrug resistance (MDR 1) in leukemia: is it time to test? Blood (1992) 1.79
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol (2005) 1.78
Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem (1995) 1.78
Disclosure of familial genetic information: perceptions of the duty to inform. Am J Med (2000) 1.77
WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature (1991) 1.75
BSACI guidelines for the management of drug allergy. Clin Exp Allergy (2009) 1.74
A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol (1996) 1.73
The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 1.73
Rocky mountain spotted fever in the eastern United States. N Engl J Med (1969) 1.72
Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem (1981) 1.71
Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol (2000) 1.69
Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med (1998) 1.67
Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol (1991) 1.63
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res (1995) 1.62